O'Connor RC - Search Results

1

Urinary Incontinence Medications: Patient-Initiated Concerns in Primary Care.

Neuner J, Schmitt E, Winn A, Davidson E, O'Connor RC, Marowski S, Luebke M, Balza J, Attewell M, Flynn KE. Neuner J, et al. Among authors: o connor rc. Urogynecology (Phila). 2024 Jun 21. doi: 10.1097/SPV.0000000000001540. Online ahead of print. Urogynecology (Phila). 2024. PMID: 38954604

2

InTone: a novel pelvic floor rehabilitation device for urinary incontinence.

Guralnick ML, Kelly H, Engelke H, Koduri S, O'Connor RC. Guralnick ML, et al. Int Urogynecol J. 2015 Jan;26(1):99-106. doi: 10.1007/s00192-014-2476-9. Epub 2014 Jul 30. Int Urogynecol J. 2015. PMID: 25074260 Clinical Trial.

3

Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity.

Guralnick ML, Grimsby G, Liss M, Szabo A, O'Connor RC. Guralnick ML, et al. Int Urogynecol J. 2010 Mar;21(3):325-9. doi: 10.1007/s00192-009-1030-7. Epub 2009 Nov 12. Int Urogynecol J. 2010. PMID: 19907912

4

Preoperative Valsalva voiding increases the risk of urinary retention after midurethral sling placement.

Pham KN, Topp N, Guralnick ML, Koduri S, Newcomer JR, O'Connor RC. Pham KN, et al. Int Urogynecol J. 2010 Oct;21(10):1243-6. doi: 10.1007/s00192-010-1177-2. Epub 2010 May 18. Int Urogynecol J. 2010. PMID: 20480139

5

Duloxetine for the treatment of post-prostatectomy stress urinary incontinence.

Neff D, Guise A, Guralnick ML, Langenstroer P, See WA, Jacobsohn KM, O'Connor RC. Neff D, et al. Can Urol Assoc J. 2013 May-Jun;7(5-6):E260-2. doi: 10.5489/cuaj.318. Can Urol Assoc J. 2013. PMID: 23766826 Free PMC article.

6

Review of female stress urinary incontinence.

Groth T, Guralnick ML, O'Connor RC. Groth T, et al. Minerva Med. 2007 Jun;98(3):203-9. Minerva Med. 2007. PMID: 17592441 Review.

7

Are there differences between women with urge predominant and stress predominant mixed urinary incontinence?

Lewis JB, Ng AV, O'Connor RC, Guralnick ML. Lewis JB, et al. Neurourol Urodyn. 2007;26(2):204-7. doi: 10.1002/nau.20359. Neurourol Urodyn. 2007. PMID: 17078089

8

Successful use of sacral neuromodulation after failed bladder augmentation.

Rasmussen NT, Guralnick ML, O'Connor RC. Rasmussen NT, et al. Can Urol Assoc J. 2009 Oct;3(5):E49-50. doi: 10.5489/cuaj.1161. Can Urol Assoc J. 2009. PMID: 19829718 Free PMC article.

9

Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.

Makovey I, Davis T, Guralnick ML, O'Connor RC. Makovey I, et al. Neurourol Urodyn. 2011 Nov;30(8):1538-40. doi: 10.1002/nau.21150. Epub 2011 Aug 8. Neurourol Urodyn. 2011. PMID: 21826718

10

Is a 50% improvement threshold adequate to justify progression from sacral neuromodulation testing to implant?

Charles DK, Everett RG, Prebay ZJ, Landowski TP, O'Connor RC, Guralnick ML. Charles DK, et al. Neurourol Urodyn. 2021 Aug;40(6):1524-1531. doi: 10.1002/nau.24698. Epub 2021 May 18. Neurourol Urodyn. 2021. PMID: 34005836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters